Eli Lilly and Nvidia announced a five‑year, up to $1 billion collaboration to build a San Francisco AI laboratory focused on accelerating drug discovery. The partnership combines Lilly’s biological data and drug‑development expertise with Nvidia’s compute, model engineering and AI infrastructure; both companies said the lab will invest in compute, data generation, and joint model development. Lilly CEO David Ricks and Nvidia CEO Jensen Huang framed the deal at JP Morgan and in press releases as a strategic step to shorten discovery timelines by integrating large‑scale biological datasets with high‑performance computing. Lilly plans to place scientists alongside Nvidia engineers to build AI models aimed at target identification, molecule design, and translational models. The pact builds on prior ties between Lilly and Nvidia and joins a wave of pharma–chipmaker partnerships. The scale and duration of the commitment reflect growing industry conviction that custom AI infrastructure and co‑developed models can materially change preclinical R&D productivity.